Fate Therapeutics (FATE) Invested Capital (2016 - 2025)
Fate Therapeutics (FATE) has disclosed Invested Capital for 14 consecutive years, with $207.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Invested Capital fell 35.0% year-over-year to $207.2 million, compared with a TTM value of $207.2 million through Dec 2025, down 35.0%, and an annual FY2025 reading of $207.2 million, down 35.0% over the prior year.
- Invested Capital was $207.2 million for Q4 2025 at Fate Therapeutics, down from $234.1 million in the prior quarter.
- Across five years, Invested Capital topped out at $790.1 million in Q1 2021 and bottomed at $207.2 million in Q4 2025.
- Average Invested Capital over 5 years is $467.4 million, with a median of $431.9 million recorded in 2023.
- The sharpest move saw Invested Capital soared 260.42% in 2021, then crashed 35.4% in 2025.
- Year by year, Invested Capital stood at $678.8 million in 2021, then decreased by 28.71% to $483.9 million in 2022, then dropped by 23.87% to $368.4 million in 2023, then decreased by 13.49% to $318.7 million in 2024, then crashed by 35.0% to $207.2 million in 2025.
- Business Quant data shows Invested Capital for FATE at $207.2 million in Q4 2025, $234.1 million in Q3 2025, and $261.4 million in Q2 2025.